Hemostemix (CVE:HEM) Trading 30% Higher – What’s Next?

Hemostemix Inc. (CVE:HEM)’s stock price was up 30% on Wednesday . The company traded as high as C$0.15 and last traded at C$0.13. Approximately 430,289 shares were traded during mid-day trading, a decline of 10% from the average daily volume of 480,285 shares. The stock had previously closed at C$0.10.

Hemostemix Trading Up 30.0%

The business’s 50-day moving average price is C$0.10 and its two-hundred day moving average price is C$0.14. The firm has a market cap of C$18.94 million, a price-to-earnings ratio of -3.79 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.

Insider Buying and Selling at Hemostemix

In other Hemostemix news, Director Peter Alan Lacey purchased 200,000 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were purchased at an average cost of C$0.15 per share, with a total value of C$30,000.00. 10.43% of the stock is currently owned by insiders.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.